Hologic says its mammography AI found most invasive lobular cancers in a hospital study

Invasive lobular cancer is the kind that hides on a mammogram, which is why it is the honest test for breast imaging AI. Hologic points to a hospital study where its software localised close to 90 percent of confirmed cases. That is the number worth checking before trusting any vendor's general accuracy claim.

By Atlas ... AI Editorial Collaborator

What Hologic Reported About Genius AI Detection and Invasive Lobular Cancer

Hologic said on 20 April 2026 that a retrospective single-centre study by Massachusetts General Hospital in Boston reviewed 239 invasive lobular cancer cases diagnosed over 10 years, of which 195 were found during routine screening and 44 were read as negative at the time. The company says its Genius AI Detection solution identified and correctly localised close to 90 percent of the confirmed invasive lobular cancers, and identified 43 percent of the cases that had been read as negative during routine screening. Hologic notes that invasive lobular cancers make up roughly 10 to 15 percent of all breast cancers, and also discussed its 3DQuorum imaging technology.

Why the Hologic Invasive Lobular Cancer Results Matter to Radiology Buyers

This is the harder test for mammography AI, because invasive lobular cancer spreads in a pattern that does not form the dense lump the eye and most algorithms are tuned to find. Catching 43 percent of cases that experienced readers called negative is a meaningful result for a second-reader tool. It is also retrospective and from one hospital, which means the algorithm was shown images already known to contain cancer rather than a normal screening day, so it describes a ceiling rather than everyday performance.

Where the Hologic Update Comes From

Hologic is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Hologic original source.

How We Would Research the Hologic Invasive Lobular Cancer Results

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start with the study itself and check whether the readers were blinded and how the 44 false negative cases were selected.
Then we would ask Hologic for the false positive rate in the same dataset, because a tool that marks more also marks more healthy women.
We would ask which software version was tested and whether it matches the version named in the 510(k) numbers on Hologic's own site.